(AKE) Arkema - Ratings and Ratios
Adhesives, Acrylics, Coatings, Polymers, Additives
AKE EPS (Earnings per Share)
AKE Revenue
Description: AKE Arkema
Arkema SA is a global specialty chemicals company operating in three main segments: Adhesive Solutions, Advanced Materials and Coating Solutions, and Intermediates, providing a wide range of products and solutions for various industries, including construction, automotive, and electronics.
The companys Adhesive Solutions segment is a significant player in the market, offering a broad portfolio of products, including sealants, adhesives, and waterproofing systems, as well as performance polymers and additives. The Advanced Materials and Coating Solutions segment provides coating solutions, additives, and specialties for various applications, including decorative paints, industrial coatings, and 3D printing.
From a financial perspective, Arkema SA has a market capitalization of approximately 4.7 billion EUR, with a price-to-earnings ratio of 16.42 and a forward P/E of 9.87, indicating a relatively stable valuation. The companys return on equity (RoE) is 4.64%, which is a moderate return. To further evaluate the companys performance, we can examine additional KPIs, such as the debt-to-equity ratio, which is around 0.63, indicating a relatively conservative debt level. The companys EBITDA margin is approximately 14%, which is a reasonable margin for a chemical company.
To assess the companys growth prospects, we can look at its revenue growth rate, which has been around 5-6% per annum over the past few years. Additionally, the companys research and development (R&D) expenses as a percentage of sales are around 2-3%, indicating a commitment to innovation and new product development. Overall, Arkema SAs diversified product portfolio, global presence, and moderate financial performance make it a stable player in the specialty chemicals industry.
AKE Stock Overview
| Market Cap in USD | 5,219m |
| Sub-Industry | Diversified Chemicals |
| IPO / Inception |
AKE Stock Ratings
| Growth Rating | -48.1% |
| Fundamental | 41.1% |
| Dividend Rating | 75.2% |
| Return 12m vs S&P 500 | -33.4% |
| Analyst Rating | - |
AKE Dividends
| Dividend Yield 12m | 5.68% |
| Yield on Cost 5y | 4.42% |
| Annual Growth 5y | 9.73% |
| Payout Consistency | 97.2% |
| Payout Ratio | 56.3% |
AKE Growth Ratios
| Growth Correlation 3m | -48.7% |
| Growth Correlation 12m | -80.8% |
| Growth Correlation 5y | -48% |
| CAGR 5y | -3.23% |
| CAGR/Max DD 3y | -0.08 |
| CAGR/Mean DD 3y | -0.30 |
| Sharpe Ratio 12m | -1.13 |
| Alpha | -38.13 |
| Beta | 0.741 |
| Volatility | 26.19% |
| Current Volume | 190.3k |
| Average Volume 20d | 156.4k |
| Stop Loss | 57.2 (-3.3%) |
| Signal | -0.37 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (226.0m TTM) > 0 and > 6% of Revenue (6% = 566.6m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -1.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 29.58% (prev 26.11%; Δ 3.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.00b > Net Income 226.0m (YES >=105%, WARN >=100%) |
| Net Debt (2.48b) to EBITDA (1.10b) ratio: 2.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.73 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (76.0m) change vs 12m ago 1.24% (target <= -2.0% for YES) |
| Gross Margin 19.02% (prev 20.74%; Δ -1.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 65.11% (prev 62.45%; Δ 2.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.15 (EBITDA TTM 1.10b / Interest Expense TTM 98.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.35
| (A) 0.20 = (Total Current Assets 4.41b - Total Current Liabilities 1.62b) / Total Assets 13.92b |
| (B) 0.32 = Retained Earnings (Balance) 4.46b / Total Assets 13.92b |
| (C) 0.02 = EBIT TTM 309.0m / Avg Total Assets 14.50b |
| (D) 0.81 = Book Value of Equity 5.22b / Total Liabilities 6.47b |
| Total Rating: 3.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.12
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 3.17% = 1.59 |
| 3. FCF Margin 2.23% = 0.56 |
| 4. Debt/Equity 0.48 = 2.38 |
| 5. Debt/Ebitda 3.19 = -2.01 |
| 6. ROIC - WACC -2.84% = -3.55 |
| 7. RoE 3.16% = 0.26 |
| 8. Rev. Trend -56.71% = -2.84 |
| 9. Rev. CAGR -7.55% = -1.26 |
| 10. EPS Trend -40.85% = -1.02 |
| 11. EPS CAGR -25.46% = -2.50 |
What is the price of AKE shares?
Over the past week, the price has changed by +1.63%, over one month by -4.52%, over three months by -1.99% and over the past year by -20.86%.
Is Arkema a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AKE is around 55.79 EUR . This means that AKE is currently overvalued and has a potential downside of -5.68%.
Is AKE a buy, sell or hold?
What are the forecasts/targets for the AKE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 76.7 | 29.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 60.4 | 2% |
AKE Fundamental Data Overview
Market Cap EUR = 4.45b (4.45b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 1.31b EUR (last quarter)
P/E Trailing = 23.4325
P/E Forward = 8.1235
P/S = 0.4713
P/B = 0.6096
P/EG = 0.4673
Beta = 1.006
Revenue TTM = 9.44b EUR
EBIT TTM = 309.0m EUR
EBITDA TTM = 1.10b EUR
Long Term Debt = 3.36b EUR (from longTermDebt, last quarter)
Short Term Debt = 147.0m EUR (from shortTermDebt, last quarter)
Debt = 3.51b EUR (Calculated: Short Term 147.0m + Long Term 3.36b)
Net Debt = 2.48b EUR (from netDebt column, last quarter)
Enterprise Value = 6.65b EUR (4.45b + Debt 3.51b - CCE 1.31b)
Interest Coverage Ratio = 3.15 (Ebit TTM 309.0m / Interest Expense TTM 98.0m)
FCF Yield = 3.17% (FCF TTM 211.0m / Enterprise Value 6.65b)
FCF Margin = 2.23% (FCF TTM 211.0m / Revenue TTM 9.44b)
Net Margin = 2.39% (Net Income TTM 226.0m / Revenue TTM 9.44b)
Gross Margin = 19.02% ((Revenue TTM 9.44b - Cost of Revenue TTM 7.65b) / Revenue TTM)
Tobins Q-Ratio = 1.27 (Enterprise Value 6.65b / Book Value Of Equity 5.22b)
Interest Expense / Debt = 0.97% (Interest Expense 34.0m / Debt 3.51b)
Taxrate = 29.59% (150.0m / 507.0m)
NOPAT = 217.6m (EBIT 309.0m * (1 - 29.59%))
Current Ratio = 2.73 (Total Current Assets 4.41b / Total Current Liabilities 1.62b)
Debt / Equity = 0.48 (Debt 3.51b / last Quarter total Stockholder Equity 7.23b)
Debt / EBITDA = 3.19 (Net Debt 2.48b / EBITDA 1.10b)
Debt / FCF = 16.62 (Debt 3.51b / FCF TTM 211.0m)
Total Stockholder Equity = 7.16b (last 4 quarters mean)
RoA = 1.62% (Net Income 226.0m, Total Assets 13.92b )
RoE = 3.16% (Net Income TTM 226.0m / Total Stockholder Equity 7.16b)
RoCE = 2.94% (Ebit 309.0m / (Equity 7.16b + L.T.Debt 3.36b))
RoIC = 2.36% (NOPAT 217.6m / Invested Capital 9.24b)
WACC = 5.20% (E(4.45b)/V(7.96b) * Re(8.75%)) + (D(3.51b)/V(7.96b) * Rd(0.97%) * (1-Tc(0.30)))
Shares Correlation 3-Years: -3.18 | Cagr: -0.28%
Discount Rate = 8.75% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.01% ; FCFE base≈328.2m ; Y1≈296.2m ; Y5≈255.8m
Fair Price DCF = 54.01 (DCF Value 4.07b / Shares Outstanding 75.4m; 5y FCF grow -12.12% → 3.0% )
EPS Correlation: -40.85 | EPS CAGR: -25.46% | SUE: -0.45 | # QB: False
Revenue Correlation: -56.71 | Revenue CAGR: -7.55%